| OAB0503 | Prevalence and incidence of tuberculosis infection and disease among household contacts exposed to rifampin-resistant/multidrug resistant tuberculosis (RR/MDR-TB) | Oral abstract session with live Q&A | B10 |
| OAB0504 | Assessment of the tuberculosis clinical cascade among children living with HIV on antiretroviral therapy, 16 Sub-Saharan PEPFAR-supported programs, October 1, 2018 to March 31, 2019 | Oral abstract session with live Q&A | B10 |
| OAB0505 | Risk factors for hepatotoxicity in HIV-infected women receiving isoniazid preventive therapy in pregnancy and postpartum | Oral abstract session with live Q&A | B10 |
| OAB0506 | Validation of a laboratory-based reference test for TB-LAM and FLOW-TB, a novel point-of-care TB diagnostic assay, in a high-HIV-prevalence clinical cohort from KwaZulu-Natal, South Africa | Oral abstract session with live Q&A | B10 |
| OAB0507 | TB contact investigations as an active HIV case finding strategy in Mozambique: Lessons for high TB and HIV syndemic countries | Oral abstract session with live Q&A | B10 |
| OAB0602 | Weight gain and hyperglycemia during the dolutegravir transition in Africa | Oral abstract session with live Q&A | B21 |
| OAB0603 | Changes in body mass index over time in persons with and without HIV | Oral abstract session with live Q&A | B22 |
| OAB0604 | Weight gain before and after switch from TDF to TAF | Oral abstract session with live Q&A | B22 |
| OAB0605 | Weight changes after switching to doravirine/lamivudine/TDF in the DRIVE-SHIFT trial | Oral abstract session with live Q&A | B22 |
| OAB0606 | Improved metabolic parameters after switching from TAF-based 3- or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study | Oral abstract session with live Q&A | B32 |